US treatment growth drives 23 percent increase in net revenue
Financial highlights Q2 2021
- Net sales amounted to 14 MSEK (11,4), an increase of 23 percent over the same period 2020.
- Operating result amounted to -9,4 MSEK (-9,0)
-
Net result after financial items amounted to -
9,7MSEK (-9,5) -
Earnings per share were -
0,15 SEK (-0,17) - Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 163 TSEK (109), an increase of 49 percent over the same period in 2020.
Financial highlights January -
- Net sales amounted to 27,2 MSEK (22,8), an increase of 19 percent over the same period 2020.
- Operating result amounted to -16,5 MSEK (-21,5)
- Net result after financial items amounted to -17,3 MSEK (-22,3)
-
Earnings per share were -
0,28 SEK (-0,40) - Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (106), an increase of 38 percent over the same period in 2020.
Significant events during the period
- The Annual General Meeting was held in
Lund in May and resolved all proposed items in accordance with the announced proposals. - In April Dignitana published the Annual Report for 2020.
Business highlights during the period
Dignitana -backed insurance legislation inTexas did not come to a full vote prior to the close of the session in May.
Business highlights after the period
- In June Dignitana launched new initiatives to support reimbursement and market access in the US.
Dignitana signed distributorB&Co Group to support Benelux Growth in July.- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency.
Q2 2021 | Q2 2020 | Q1-Q2 2021 | Q1-Q2 2020 | Full year 2020 | |
Net revenues, TSEK | 14 038 | 11 423 | 27 203 | 22 816 | 46 629 |
Total revenues, TSEK | 17 174 | 11 876 | 31 331 | 24 353 | 49 956 |
Net profit after financial items, TSEK | -9 660 | -9 528 | -17 324 | -22 283 | -52 963 |
Cash and bank balances, TSEK | 36 333 | 7 484 | 36 333 | 7 484 | 78 770 |
Earnings per share before and after dilution, SEK | -0,15 | -0,17 | -0,28 | -0,40 | -0,96 |
Average Daily Treatment Revenue*, TSEK | 163 | 109 | 146 | 106 | 120 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that
For More Information Contact
About
https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q2-2021-interim-report,c3399368
https://mb.cision.com/Main/2116/3399368/1455974.pdf
(c) 2021 Cision. All rights reserved., source